ENHANZE(®) drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20

ENHANZE(®) drug delivery technology is based on the proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20; Halozyme Therapeutics, Inc.) that facilitates the subcutaneous (SC) delivery of co‐administered therapeutics. rHuPH20 works by degrading the glycosaminoglycan hyaluronan (HA), which...

Descripción completa

Detalles Bibliográficos
Autores principales: Locke, Kenneth W., Maneval, Daniel C., LaBarre, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394283/
https://www.ncbi.nlm.nih.gov/pubmed/30744432
http://dx.doi.org/10.1080/10717544.2018.1551442

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394283/
https://www.ncbi.nlm.nih.gov/pubmed/30744432
http://dx.doi.org/10.1080/10717544.2018.1551442

Ejemplares similares